| Literature DB >> 30081568 |
Anna Carbone1, Barbara Parrino2, Maria Grazia Cusimano3, Virginia Spanò4, Alessandra Montalbano5, Paola Barraja6, Domenico Schillaci7, Girolamo Cirrincione8, Patrizia Diana9, Stella Cascioferro10.
Abstract
New thiazole nortopsentin analogues were conveniently synthesized and evaluated for their activity as inhibitors of biofilm formation of relevant Gram-positive and Gram-negative pathogens. All compounds were able to interfere with the first step of biofilm formation in a dose-dependent manner, showing a selectivity against the staphylococcal strains. The most active derivatives elicited IC50 values against Staphylococcus aureus ATCC 25923, ranging from 0.40⁻2.03 µM. The new compounds showed a typical anti-virulence profile, being able to inhibit the biofilm formation without affecting the microbial growth in the planktonic form.Entities:
Keywords: anti-virulence agents; antibiofilm agents; marine alkaloids; nortopsentin analogues; thiazole derivatives
Mesh:
Substances:
Year: 2018 PMID: 30081568 PMCID: PMC6117647 DOI: 10.3390/md16080274
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
New thiazole derivatives 1a–p.
| Compd. | R | R1 | R2 | Compd. | R | R1 | R2 |
|---|---|---|---|---|---|---|---|
|
| H | CH2CH2NHBoc | H |
| H | CH2CH2NH2 | H |
|
| H | CH2CH2NHBoc | Me |
| H | CH2CH2NH2 | Me |
|
| OMe | CH2CH2NHBoc | H |
| OMe | CH2CH2NH2 | H |
|
| OMe | CH2CH2NHBoc | Me |
| OMe | CH2CH2NH2 | Me |
|
| Br | CH2CH2NHBoc | H |
| Br | CH2CH2NH2 | H |
|
| Br | CH2CH2NHBoc | Me |
| Br | CH2CH2NH2 | Me |
|
| F | CH2CH2NHBoc | H |
| F | CH2CH2NH2 | H |
|
| F | CH2CH2NHBoc | Me |
| F | CH2CH2NH2 | Me |
Thiazole derivatives 2a–u [39].
| Compd. | R | R1 | R2 | Compd. | R | R1 | R2 |
|---|---|---|---|---|---|---|---|
|
| H | CH2CH2OMe | H |
| Br | Me | CH2CH2OMe |
|
| H | CH2CH2OMe | Me |
| F | CH2CH2OMe | H |
|
| H | CH2CH2OMe | CH2CH2OMe |
| F | CH2CH2OMe | Me |
|
| H | Me | CH2CH2OMe |
| F | CH2CH2OMe | CH2CH2OMe |
|
| OMe | CH2CH2OMe | H |
| F | Me | CH2CH2OMe |
|
| OMe | CH2CH2OMe | Me |
| F | H | CH2CH2OMe |
|
| OMe | CH2CH2OMe | CH2CH2OMe |
| H | Boc | CH2CH2OMe |
|
| OMe | Me | CH2CH2OMe |
| Br | Boc | CH2CH2OMe |
|
| Br | CH2CH2OMe | H |
| H | H | CH2CH2OMe |
|
| Br | CH2CH2OMe | Me |
| Br | H | CH2CH2OMe |
|
| Br | CH2CH2OMe | CH2CH2OMe |
Scheme 1Synthesis of new thiazoles 1i–p. Reagents: (i) (a) CSI, MeCN, 0 °C, 2 h; (b) DMF, 0 °C, 2 h, 90–98%; (ii) (a), NaH, DMF, 0 °C-rt, 30 min; (b) BrCH2CH2NHBoc, 60 °C, 24 h, 61–82%; (iii) P4S10, EtOH, rt, 1 h; then reflux, 24 h, 60–72%; (iv) EtOH, reflux, 30 min, 61–87%; (v) (a) TFA, DCM, reflux, 24 h; (b) aq NaHCO3, 60–91%.
Inhibition of biofilm formation, IC50 (µM).
| Compd. | ||||||
|---|---|---|---|---|---|---|
|
| 3.9 ± 0.2 | 8.4 ± 0.4 | 5.2 ± 0.3 | 11.3 ± 0.6 | - | - |
|
| 13.8 ± 0.9 | 29.1 ± 1.9 | 19.3 ± 1.1 | 40.7 ± 2.3 | 15.6 ± 1.1 | 32.9 ± 2.3 |
|
| 7.1 ± 0.1 | 14.5 ± 0.2 | 11.6 ± 0.9 | 23.6 ± 1.8 | - | - |
|
| 14.1 ± 1.0 | 27.9 ± 2.0 | 13.1 ± 0.5 | 26.0 ± 1.0 | - | - |
|
| 9.3 ± 0.9 | 16.8 ± 1.6 | 6.5 ± 0.5 | 11.7 ± 0.9 | 37.2 ± 2.5 | 67.3 ± 4.5 |
|
| 36.9 ± 1.7 | 75.0 ± 3.4 | 9.3 ± 0.4 | 18.9 ± 0.8 | 13.1 ± 0.8 | 26.6 ± 1.6 |
|
| 4.7 ± 0.3 | 13.0 ± 0.8 | 9.7 ± 0.9 | 26.9 ± 2.5 | 22.7 ± 2.1 | 63.1 ± 5.8 |
|
| 32.9 ± 3.1 | 88.0 ± 8.3 | 6.2 ± 0.09 | 16.6 ± 0.2 | 56.1 ± 3.2 | 150.2 ± 8.6 |
|
| 23.3 ± 1.5 | 59.2 ± 3.8 | 4.8 ± 0.1 | 12.3 ± 0.3 | 4.2 ± 0.1 | 10.7 ± 0.2 |
|
| 48.7 ± 2.2 | 120.6 ± 5.4 | 7.2 ± 0.7 | 17.8 ± 1.7 | 24.2 ± 0.8 | 59.9 ± 2.0 |
|
| 4.4 ± 0.1 | 10.0 ± 0.2 | 3.3 ± 0.08 | 7.5 ± 0.2 | 7.8 ± 0.09 | 17.7 ± 0.2 |
|
| 20.1 ± 0.8 | 44.4 ± 1.8 | 5.4 ± 0.2 | 11.9 ± 0.4 | 4.6 ± 0.1 | 10.1 ± 0.2 |
|
| 1.5 ± 0.1 | 3.9 ± 0.3 | 6.3 ± 0.4 | 16.6 ± 1.0 | 4.5 ± 0.4 | 11.9 ± 1.1 |
|
| 0.5 ± 0.02 | 1.27 ± 0.05 | 5.2 ± 0.08 | 13.2 ± 0.2 | 3.9 ± 0.07 | 9.9 ± 0.2 |
|
| 7.5 ± 0.2 | 19.3 ± 0.5 | - | - | - | - |
|
| 18.6 ± 0.9 | 45.9 ± 2.2 | 25.4 ± 1.7 | 62.7 ± 4.2 | 20.5 ± 1.2 | 50.6 ± 3.0 |
|
| 1.2 ± 0.03 | 2.8 ± 0.07 | 11.5 ± 0.7 | 26.7 ± 1.6 | - | - |
|
| 7.9 ± 0.6 | 17.0 ± 1.3 | 11.1 ± 0.2 | 23.9 ± 0.4 | 17.7 ± 0.8 | 38.2 ± 1.7 |
|
| 0.79 ± 0.009 | 1.7 ± 0.02 | 9.4 ± 0.3 | 20.7 ± 0.7 | 4.4 ± 0.08 | 9.7 ± 0.2 |
|
| 0.95 ± 0.01 | 2.03 ± 0.02 | 11.2 ± 1.1 | 23.9 ± 2.3 | 19.1 ± 0.1 | 40.8 ± 0.2 |
|
| 2.9 ± 0.02 | 5.6 ± 0.04 | 18.8 ± 1.5 | 36.7 ± 2.9 | - | - |
|
| 2.5 ± 0.02 | 5.3 ± 0.04 | - | - | - | - |
|
| 13.8 ± 0.7 | 35.1 ± 1.8 | 0.3 ± 0.002 | 0.7 ± 0.005 | - | - |
|
| 0.2 ± 0.006 | 0.4 ± 0.012 | 21.0 ± 1.7 | 51.6 ± 4.2 | - | - |
|
| 28.5 ± 1.9 | 63.2 ± 4.2 | - | - | - | - |
|
| 13.7 ± 1.1 | 34.9 ± 2.8 | 23.1 ± 1.9 | 58.8 ± 4.8 | - | - |
|
| 1.8 ± 0.1 | 3.7 ± 0.2 | 6.9 ± 0.1 | 14.5 ± 0.2 | - | - |
|
| 12.9 ± 0.5 | 34.4 ± 1.3 | 7.5 ± 0.6 | 20.0 ± 1.6 | 16.3 ± 1.3 | 43.5 ± 3.5 |
|
| 13.1 ± 0.8 | 28.8 ± 1.7 | 9.6 ± 0.9 | 21.1 ± 2.0 | - | - |
Figure 1Inhibition of sortase activity by sortase inhibitor 4-(hydroxymercuri)benzoic acid (red) and 1a (purple) and 2r (green) and the negative control (blue) as measured with SensoLyte® 520 Sortase A assay kit.